| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Henrik Renner, Hans R Schöler, Jan M Brude. Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond. Movement disorders : official journal of the Movement Disorder Society. 2021-09-20. PMID:34498298. |
parkinson's disease (pd) is the second most common neurodegenerative disease and primarily characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. |
2021-09-20 |
2023-08-13 |
human |
| Niki Shrestha, Rose Anne M Abe, Anum Masroor, Arseni Khorochkov, Jose Prieto, Karan B Singh, Maduka C Nnadozie, Muhammad Abdal, Lubna Mohamme. The Correlation Between Parkinson's Disease and Rapid Eye Movement Sleep Behavior Disorder: A Systematic Review. Cureus. vol 13. issue 8. 2021-09-16. PMID:34522507. |
parkinson's disease (pd) is a neurodegenerative disease caused due to the destruction of dopaminergic neurons and the deposition of α-synuclein proteins, known as lewy bodies. |
2021-09-16 |
2023-08-13 |
human |
| Mustafa T Ardah, Greeshma Bharathan, Tohru Kitada, M Emdadul Haqu. Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson's Disease. Biomolecules. vol 10. issue 11. 2021-09-02. PMID:33172035. |
parkinson's disease (pd) is one of the most common neurodegenerative diseases and is characterized by progressive dopaminergic neurodegeneration in the substantia nigra pars compacta area. |
2021-09-02 |
2023-08-13 |
Not clear |
| Li Zou, Xingyu Zhang, Min Xiong, Lanxia Meng, Ye Tian, Lina Pan, Xin Yuan, Guiqin Chen, Zhihao Wang, Lihong Bu, Zhaohui Yao, Zhaohui Zhang, Keqiang Ye, Zhentao Zhan. Asparagine endopeptidase cleaves synaptojanin 1 and triggers synaptic dysfunction in Parkinson's disease. Neurobiology of disease. vol 154. 2021-09-02. PMID:33677035. |
parkinson's disease (pd) is one of the most common neurodegenerative diseases, which is characterized by the loss of dopaminergic neurons in the nigrostriatal pathway. |
2021-09-02 |
2023-08-13 |
mouse |
| Luca Magistrelli, Elena Contaldi, Cristoforo Com. The Impact of Life (Basel, Switzerland). vol 11. issue 8. 2021-08-31. PMID:34440548. |
the impact of parkinson's disease (pd) is a common and progressive neurodegenerative disease, caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain, which is clinically characterized by a constellation of motor and non-motor manifestations. |
2021-08-31 |
2023-08-13 |
Not clear |
| Victor A D Holanda, Julia J Didonet, Manara B B Costa, Adriano H do Nascimento Rangel, Edilson D da Silva, Elaine C Gaviol. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451872. |
parkinson disease (pd) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. |
2021-08-31 |
2023-08-13 |
rat |
| Andrew Schneider, Adam T Sari, Hasan Alhaddad, Youssef Sar. Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease. CNS & neurological disorders drug targets. vol 19. issue 3. 2021-08-30. PMID:32448109. |
parkinson's disease (pd) is a neurodegenerative disease involving degeneration of dopaminergic neurons of the nigrostriatal pathways. |
2021-08-30 |
2023-08-13 |
Not clear |
| Heng-Chung Kung, Kai-Jung Lin, Chia-Te Kung, Tsu-Kung Li. Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson's Disease. Biomedicines. vol 9. issue 8. 2021-08-30. PMID:34440122. |
parkinson's disease (pd) is the second most common neurodegenerative disease and is characterized by dopaminergic neuronal loss. |
2021-08-30 |
2023-08-13 |
Not clear |
| Guoxue Zhu, Wang Wang, Chang Chen, Lili Tang, Yan Liang, Zhennian Zhang, Yan Lu, Yang Zha. UHPLC-MS-based metabolomics and chemoinformatics study reveals the neuroprotective effect and chemical characteristic in Parkinson's disease mice after oral administration of Wen-Shen-Yang-Gan decoction. Aging. vol 13. issue 15. 2021-08-28. PMID:34339394. |
parkinson's disease (pd), the typical neurodegenerative disease, is characterized by the progressive loss of dopaminergic neurons in the substantia nigra (sn). |
2021-08-28 |
2023-08-13 |
mouse |
| Cassandra Thompson, Paulina Otero, Bhairavi Srinageshwar, Robert B Petersen, Gary L Dunbar, Julien Rossigno. Possible roles of epigenetics in stem cell therapy for Parkinson's disease. Epigenomics. vol 12. issue 7. 2021-08-26. PMID:32396465. |
parkinson's disease (pd) is a neurodegenerative disease with loss of dopaminergic neurons. |
2021-08-26 |
2023-08-13 |
Not clear |
| Karim Belarbi, Elodie Cuvelier, Marie-Amandine Bonte, Mazarine Desplanque, Bernard Gressier, David Devos, Marie-Christine Chartier-Harli. Glycosphingolipids and neuroinflammation in Parkinson's disease. Molecular neurodegeneration. vol 15. issue 1. 2021-08-26. PMID:33069254. |
parkinson's disease is a progressive neurodegenerative disease characterized by the loss of dopaminergic neurons of the nigrostriatal pathway and the formation of neuronal inclusions known as lewy bodies. |
2021-08-26 |
2023-08-13 |
human |
| V Morales, J McConnell, M Pérez-Garnes, N Almendro, R Sanz, R A García-Muño. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease. Journal of materials chemistry. B. vol 9. issue 20. 2021-08-20. PMID:33989370. |
parkinson's disease (pd) is a progressive neurodegenerative disease, the 2nd most common after alzheimer's disease, the main effect of which is the loss of dopaminergic neurons. |
2021-08-20 |
2023-08-13 |
Not clear |
| Ilker Ozsahin, Boran Sekeroglu, Pwadubashiyi Coston Pwavodi, Greta S P Mo. High-accuracy Automated Diagnosis of Parkinson's Disease. Current medical imaging. vol 16. issue 6. 2021-08-18. PMID:32723240. |
parkinson's disease (pd), which is the second most common neurodegenerative disease following alzheimer's disease, can be diagnosed clinically when about 70% of the dopaminergic neurons are lost and symptoms are noticed. |
2021-08-18 |
2023-08-13 |
Not clear |
| Eun-Mi Hur, Byoung Dae Le. LRRK2 at the Crossroad of Aging and Parkinson's Disease. Genes. vol 12. issue 4. 2021-08-16. PMID:33805527. |
parkinson's disease (pd) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as lewy bodies and lewy neurites. |
2021-08-16 |
2023-08-13 |
Not clear |
| Falaq Naz, Rahul, Mahino Fatima, Swaleha Naseem, Wasi Khan, Amal Chandra Mondal, Yasir Hasan Siddiqu. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology. vol 177. 2021-08-12. PMID:32707222. |
parkinson's disease (pd) is a progressive neurodegenerative disease due to the degeneration of dopaminergic neurons in substantia nigra pars compacta of the mid brain. |
2021-08-12 |
2023-08-13 |
drosophila_melanogaster |
| Marianne Amalric, Tommy Pattij, Ioannis Sotiropoulos, Joana M Silva, Nuno Sousa, Samira Ztaou, Cristiano Chiamulera, Lars U Wahlberg, Dwaine F Emerich, Giovanna Paolon. Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders. Frontiers in behavioral neuroscience. vol 15. 2021-08-10. PMID:34366802. |
historically, many investigations into neurodegenerative diseases have focused on alterations in specific neuronal populations such as, for example, the loss of midbrain dopaminergic neurons in parkinson's disease (pd) and loss of cholinergic transmission in alzheimer's disease (ad). |
2021-08-10 |
2023-08-13 |
human |
| Yaru Dong, Jing Xiong, Liya Ji, Xiuyun Xu. MiR-421 Aggravates Neurotoxicity and Promotes Cell Death in Parkinson's Disease Models by Directly Targeting MEF2D. Neurochemical research. vol 46. issue 2. 2021-08-09. PMID:33179210. |
parkinson's disease (pd) is a severe neurodegenerative disease characterized by selective loss of dopaminergic neurons, which reduces quality of life of patients and poses a heavy burden to the society. |
2021-08-09 |
2023-08-13 |
Not clear |
| Yeojin Bang, Juhee Lim, Hyun Jin Cho. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment. Archives of pharmacal research. vol 44. issue 6. 2021-08-04. PMID:34145553. |
parkinson's disease (pd) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. |
2021-08-04 |
2023-08-13 |
Not clear |
| Derya Cansız, Unsal Veli Ustundag, Ismail Unal, A Ata Alturfan, Ebru Emekli-Alturfa. Morphine attenuates neurotoxic effects of MPTP in zebrafish embryos by regulating oxidant/antioxidant balance and acetylcholinesterase activity. Drug and chemical toxicology. 2021-08-03. PMID:34340603. |
parkinson's disease (pd) is one of the most common neurodegenerative diseases due to the loss of dopaminergic neurons in the midbrain in the substantia nigra. |
2021-08-03 |
2023-08-13 |
zebrafish |
| Anna Gasiorowska, Malgorzata Wydrych, Patrycja Drapich, Maciej Zadrozny, Marta Steczkowska, Wiktor Niewiadomski, Grazyna Niewiadomsk. The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. Frontiers in aging neuroscience. vol 13. 2021-07-31. PMID:34326765. |
here, we review human studies and studies on mice and rats, such as those modeling human neurodegenerative diseases, that have helped elucidate (1) the dynamics and mechanisms underlying the biological and pathological aging of the main projecting systems in the brain (glutamatergic, cholinergic, and dopaminergic) and (2) the effect of defective glutamatergic, cholinergic, and dopaminergic projection on disabilities associated with aging and neurodegenerative disorders, such as alzheimer's and parkinson's diseases. |
2021-07-31 |
2023-08-13 |
mouse |